Sign in
PEAR Stock Price, Chart, Stats & News
Pear Therapeutics, Inc.
Save
4.09M
Market cap
–
Current P/E
–
Forward P/E
PEAR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 35.54% |
Operating margin | -971.72% |
Pretax margin | -594.70% |
Net margin | -187.02% |
Effective tax rate | 68.55% |
ROA | -24.96% |
ROE | -39.23% |
D/E | 1.23x |
Interest coverage ratio | -31.69x |
PEAR valuation
P/E | – |
P/S | 0.32x |
P/B | 0.13x |
P/CF | -0.04x |
P/FCF | -0.03x |
P/OCF | -0.04x |
PEG | -0.00x |
EV multiple | -0.09x |
About
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products.
Similar securities
Based on sector and market capitalization
Report issue